c-myc is not useful as prognostic immunohistochemical marker in cutaneous melanoma

Dermatology

Volumn 196, Issue 3, 1998, Pages 288-291

  Boni R ^a   Bantschapp, O ^a   Muller B ^a   Burg, G ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

c myc; Immunohistochemistry; Melanoma; Oncogene; Prognosis

Indexed keywords

ARTICLE; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS POTENTIAL; ONCOGENE C MYC; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 2642695720     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000017922     Document Type: Article

References (18)

1. Breslow A: Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970;172:902-908.
2. Soong SJ, Shaw HM, Balch CM, McCarthy WH, Urist MM, Lee JY: Predicting survival and recurrence in localized melanoma: A multivariate approach. World J Surg 1992;16:191-195.
3. Böni R, Doguoglu A, Burg G, Müller B, Dummer R: MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma. J Am Acad Dermatol 1996;35:416-418.
4. Lazaris AC, Theodoropoulos GE, Aroni K, Saetta A, Davaris PS: Immunohistochemical expression of c-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma. Virchows Arch 1995;426:461-467.
5. Mooy CM, Luzten GP, de Jong PT, Under TM, Stijnen T, van de Ham F, van Vroonhoven CC, Bosman FT: Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma. Am J Pathol 1995;147:1097-1104.
6. Vogelstein B, Kinzler KW: The multistep nature of cancer. Trends Genet 1993;9:138-141.
7. Alitalo K, Bishop JM, Smith DH, Chen EY, Colby WW, Levinson AD: Nucleotide sequence to the v-myc oncogene of avian retrovirus MC29. Proc Natl Acad Sci USA 1983;80:100-104.
8. Cole MD: Activation of the c-myc oncogene. Basic Life Sci 1986;38:399-406.
9. Cole MD: Regulation and activation of c-myc. Nature 1985:318:510-511.
10. Spencer CA, Groudine M: Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res 1991;56:1-48.
11. Ahern TE, Bird RC, Bird AE, Wolfe LG: Over-expression of c-erbB-2 and c-myc but not c-ras, in canine melanoma cell lines is associated with metastatic potential in nude mice. Anticancer Res 1993;13:1365-1371.
12. Korabiowska M, Brinck U, Mirecka J, Kellner S, Marx D, Schauer A: Antigen Ki-67 and c-myc oncogene as related to histoclinical parameters in pigmented skin lesions. In Vivo 1995;9:433-438.
13. Blom DJ, Mooy CM, Luyten GP, Kerkvliet S, Ouwerkerk I, Zwinderman AH, Schrier PI, Jager MJ: Inverse correlation between expression of HLA-B and c-myc in uveal melanoma. J Pathol 1997;181:75-79.
14. Grover R, Grobbelaar AO, Hudson DA, Forder M, Wilson GD, Sanders R: The clinical significance of oncogene expression in sublingual melanoma. Br J Plast Surg 1997;50:15-19.
15. Mason DY, Cordell JL, Abdulaziz Z, Naiem M, Bordenave G: Preparation of peroxidase:antiperoxidase (PAP) complexes for immunohistological labeling of monoclonal antibodies. J Histochem Cytochem 1982;30:1114-1122.
16. Peltenburg LT, Steegenga WT, Kruse KM, Schrier PI: c-myc-induced natural killer cell sensitivity of human melanoma cells is reversed by HLA-B27 transfection. Eur J Immunol 1992;22:2737-2740.
17. Griffioen M, Peltenburg LT, van Oorschot DA, Schrier PI: c-myc represses transiently transfected HLA class I promoter sequences not locus-specifically. Immunobiology 1995;193:238-247.
18. Alarcon RM, Rupnow BA, Graeber TG, Knox SJ, Giaccia AJ: Modulation of c-myc activity and apoptosis in vitro. Cancer Res 1996;56:4315-4319.